Ionis and AstraZeneca Advance New Drug for NASH
- Category: Small Molecules
- Published on Monday, 09 April 2018 15:00
- Hits: 858
Ionis earns $30 million license fee for IONIS-AZ6-2.5-L Rx
Third drug to enter development under strategic cardiovascular-renal-metabolic collaboration with AstraZeneca
CARLSBAD, CA, USA I April 9, 2018 I Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH). In conjunction with this milestone, global, science-led biopharmaceutical company AstraZeneca will pay a $30 million license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx.
"This is the third drug to enter development under our strategic collaboration with AstraZeneca to discover drugs to treat cardiovascular, renal and metabolic diseases. IONIS-AZ6-2.5-LRx incorporates many of the advancements we have made in antisense technology, including our LIgand-Conjugated Antisense (LICA) and Generation 2.5 chemistry, and is the second drug in our collaboration to incorporate both modifications. By combining Generation 2.5 and LICA, we generate drugs that have the advantages of both higher affinity chemistry and efficient cell-specific targeting. This combination provides us with drugs that are substantially more potent than either Generation 2.5 or LICA alone, and supports administration of infrequent, very low doses, and even enables the potential for oral dosing," said Brett P. Monia, chief operating officer, senior vice president of antisense drug discovery and translational medicine at Ionis Pharmaceuticals. "We are pleased with how quickly we moved IONIS-AZ6-2.5-LRx from target validation into development, exemplifying the efficiency of our antisense platform. AstraZeneca has played a strategic role in advancing this program forward by providing both preclinical and development expertise in NASH that has contributed to the rapid advance of this drug into development. We look forward to AstraZeneca moving this program swiftly into clinical testing and ultimately to the market."
As IONIS-AZ6-2.5-LRx advances in development, Ionis may also receive up to $300 million in additional development and regulatory milestone payments, as well as tiered royalties up to the low teens from sales of the drug.
ABOUT IONIS AND ASTRAZENECA
AstraZeneca and Ionis have a strategic alliance focused on leveraging antisense technology to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The collaboration builds on a broad existing relationship between the two companies and is supported by Ionis' expertise in cardiovascular disease and antisense technology and AstraZeneca's drug development expertise and infrastructure. In the collaboration, Ionis is primarily responsible for creating development candidates. AstraZeneca paid Ionis an upfront fee of $65 million at the initiation of the collaboration. Beyond AZD2693, AstraZeneca has the option to license additional antisense drugs upon development candidate nomination and will pay a license fee for each drug licensed plus development and regulatory milestones and sales royalties for each program that AstraZeneca advances. Ionis and AstraZeneca are also collaborating to discover and develop antisense drugs to treat cancer.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 40 drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen, an antisense drug Ionis is developing to treat patients with hereditary ATTR (hATTR) amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics, Inc. to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious rare diseases. If approved, inotersen and volanesorsen will be commercialized through Ionis' affiliate, Akcea. Inotersen is under regulatory review in the U.S. and EU. Volanesorsen is under regulatory review in the U.S., EU, and Canada. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
SOURCE: IONIS Pharmaceuticals